India steps up drug-quality enforcement with 950 actions since 2022
The government has initiated 950 enforcement actions against drug manufacturers since December 2022 and audited more than 1,100 cough syrup makers, tightening scrutiny of quality controls, manufacturing practices and recalls across India’s pharma supply chain.
What happened
Central Drugs Standard Control Organisation (CDSCO) · India’s drug regulator has initiated 950 actions against manufacturers since December 2022 and intensified
Key facts
- 950 enforcement actions since December 2022
- More than 1,100 cough syrup manufacturers audited
- About 10,500 drug manufacturing units in India
- Drugs and Cosmetics Act, 1940
- Drugs Rules, 1945
Why this matters
Acquirers should expand diligence on GMP compliance, inspection history, product-quality systems and recall exposure when evaluating Indian pharma targets.
What to watch
- New CDSCO or state regulator license suspensions, product recalls and warning notices involving major suppliers.
- Evidence of shortages or wholesale price increases in cough syrups, pediatric formulations, antibiotics or common generics.
- Expansion of mandatory risk-based inspections, GMP deadlines, track-and-trace requirements or retailer recordkeeping rules.
- Manufacturer consolidation, capacity shutdowns or distributor payment-term changes following enforcement actions.
- Consumer and physician shifts toward large branded manufacturers or organized pharmacy chains after high-profile quality incidents.
- Audit exposure to cough syrup, pediatric medicine and low-cost generic suppliers; identify single-source and high-recall-risk SKUs.
- Increase procurement from GMP-compliant, traceable manufacturers and prequalify substitute brands for high-velocity medicines.
- Tighten batch-level receiving, expiry, recall and supplier-documentation controls across stores and distribution centers.
- Build targeted safety stock for essential medicines while avoiding broad inventory accumulation in regulated price-sensitive categories.
- Prepare customer-service and store protocols for rapid product withdrawals, substitutions and prescription-related communication.